Medherant

Medherant

Signal active

Organization

Contact Information

Overview

Medherant was founded by Professor David Haddleton and the University of Warwick to develop and commercialise novel transdermal drug delivery platforms. Current patch technologies have limited drug loading capabilities, making them unviable for use with many pharmaceutical products that could benefit from transdermal delivery. Creams and gels on the other hand suffer from a lack of dose control that is critical for many drugs.

About

Industries

Pharmaceutical, Delivery, Commercial

Founded

2015

Employees

1-10

Headquarters locations

Coventry, Coventry, United Kingdom, Europe

Social

Profile Resume

Medherant headquartered in Europe, operates in the Pharmaceutical, Delivery, Commercial sector. The company focuses on Pharmaceutical and has secured $674.8M in funding across 60 round(s). With a team of 1-10 employees, Medherant is actively contributing to advancements in Pharmaceutical. Their latest funding round, Seed Round - Medherant, raised $1.9M. Discover more about their projects, partnerships, and impact on our platform.

Employees

imagePlace John Burt

John Burt

Chief Executive Officer

Funding Rounds

Funding rounds

5

Investors

1

Lead Investors

0

Total Funding Amount

$11.2M

Details

2

Medherant has raised a total of $11.2M in funding over 2 rounds.

Announcement dateTransaction nameNumber of InvestorsMoney raisedLead Investor
2019Early Stage Venture2.2M
2016Seed1.9M

Investors

Medherant is funded by 13 investors.

Investor NameLead InvestorFunding RoundPartners
Mercia Asset Management-FUNDING ROUND - Mercia Asset Management3.6M
Mark Payton-FUNDING ROUND - Mark Payton1.9M
Medherant-FUNDING ROUND - Medherant1.9M
Mercia Asset Management-FUNDING ROUND - Mercia Asset Management1.9M